Sign In
Buy DTCFF
$0.299
+0.0178 (+6.31%)
At Close: Jul 31, 2026
Defence Therapeutics Announces Debenture Units Financing
08:30pm, Friday, 22'nd Aug 2025
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug
Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
03:15am, Monday, 14'th Jul 2025
Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
03:15am, Monday, 09'th Jun 2025
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
03:15am, Monday, 02'nd Jun 2025
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in adva
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
03:15am, Wednesday, 28'th May 2025
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advance
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
03:15am, Tuesday, 08'th Apr 2025
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advan
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
03:15am, Wednesday, 26'th Mar 2025
Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radio
Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million
06:00pm, Friday, 31'st Jan 2025
Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing rad
Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radi
Defence Fortifies Patent Portfolio
03:15am, Monday, 06'th Jan 2025
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company deve
Defence Arranges Financing
04:30pm, Tuesday, 31'st Dec 2024
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company de
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors
03:15am, Friday, 20'th Dec 2024
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company d
Defence Provides Update on Delivery of AGSM Proxy Materials
07:00pm, Monday, 02'nd Dec 2024
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company dev
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
06:00pm, Friday, 29'th Nov 2024
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company de
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
03:15am, Monday, 25'th Nov 2024
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company de
